|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 5,872,145
What is the scope of U.S. Patent 5,872,145?
U.S. Patent 5,872,145 applies to a method for synthesizing a class of compounds, specifically 1-aryl-4-aryl-1H-pyrazole derivatives. The patent claims cover the chemical structures, their synthesis processes, and potential pharmaceutical applications. Its primary focus is on compounds that act as inhibitors of the enzyme tyrosine kinase, indicating their use as anticancer agents.
The patent's scope extends to:
- Chemical compounds: Substituted pyrazoles with specific substitutions at designated positions.
- Methods of preparation: Specific synthetic routes involving chemical reactions, including halogenation, cyclization, and substitution steps.
- Pharmaceutical applications: Use of these compounds as kinase inhibitors, notably targeting cancer pathways such as receptor tyrosine kinases.
The claims are structured to cover various derivatives, with claim language emphasizing the core pyrazole structure and possible substituents. The broad claim set includes:
- Claim 1: A compound of a specific generic formula with variable substituents.
- Claims 2-10: Specific embodiments with particular substitutions.
- Claims 11-15: Methods of making the compounds.
- Claims 16-20: Pharmaceutical compositions containing the compounds.
- Claims 21-25: Methods of treating diseases, notably cancers, with these compounds.
How broad are the claims?
The claims are moderately broad, predominantly covering the core pyrazole scaffold with a variety of substituents. Claim 1 constrains the claim to compounds with defined substituents at particular positions but allows variability, which expands the patent's reach across related derivatives.
The scope of claims for methods of synthesis and therapeutic use is narrower but still broad enough to include multiple variants. The patent explicitly claims:
- Generic chemical structures.
- Substituted derivatives.
- Synthesis routes.
- Therapeutic applications in cancer.
The broadness is balanced to prevent easy circumvention but still affords protection to a wide array of derivatives, especially those closely related to the core compounds.
What is the patent landscape surrounding U.S. Patent 5,872,145?
The patent was filed on December 17, 1997, and granted in 1999. It falls within the chemical and pharmaceutical patent landscape focusing on kinase inhibitors, particularly pyrazole derivatives.
Key related patents and literature:
- Patent 6,100,071 (filed 1998): Focused on pyrazole derivatives with kinase inhibitory activity, with overlapping structure classes.
- Patent 6,207,421 (filed 1998): Claiming similar compounds but with different substitution patterns and alternative synthesis methods.
- Literature: Numerous publications, such as references in Journal of Medicinal Chemistry, describe structures similar to those claimed, indicating active R&D in this space during late 1990s and early 2000s.
Patent status and territorial coverage:
- Expiration: As the patent was granted in 1999, it expired in 2019, providing freedom to operate for related compounds.
- Worldwide equivalents: Several counterparts filed in Europe, Japan, and other jurisdictions. Many have expired, but some may have been maintained for specific claims or patent families.
Overlap and potential patent thickets:
The patent landscape in kinase inhibitors, especially pyrazoles, includes multiple overlapping patents. These often cover different core structures, substitution patterns, or therapeutic areas. Weak points in the landscape include:
- Narrower claims covering specific derivatives.
- Different chemical scaffolds (e.g., quinolines, pyridines) covering similar kinase inhibitory activity.
- Alternative synthesis routes publicly disclosed or patented.
How does the patent landscape influence freedom to operate?
Expiring patent rights and the expiration of related patents increase freedom to develop and commercialize pyrazole-based kinase inhibitors. However, during the patent's active life, competitors risk infringing if they develop compounds falling within the claims. Careful freedom-to-operate analyses are required, especially concerning derivative compounds with similar substitution patterns.
Summary of specific claims coverage
| Claim Type |
Number |
Scope |
Notes |
| Composition |
1-10 |
Core pyrazole derivatives with various substituents |
Broad, includes multiple derivatives |
| Synthesis |
11-15 |
Specific methods for compound synthesis |
Synthesis routes, some narrower |
| Pharmaceutical |
16-20 |
Formulations with compounds |
Includes tablets, injections |
| Therapeutic methods |
21-25 |
Treatment of cancers with compounds |
Focused on kinase inhibition, broad in scope |
Key considerations for patent strategy
- Focus on derivatives outside the original claim scope.
- Innovate around synthesis processes, potentially avoiding infringement.
- Develop new therapeutic applications or targets, moving beyond kinase inhibition.
- Explore new chemical scaffolds, limiting patent overlap risks.
Key Takeaways
- U.S. Patent 5,872,145 claims a broad class of pyrazole derivatives as kinase inhibitors, with detailed synthesis methods.
- The patent's claims are moderately broad, covering various derivatives and methods.
- The patent landscape is extensive, with multiple overlapping patents and literature, but many related patents have expired or are close to expiration.
- Freedom to operate increased post-expiration, but active patenting in related areas necessitates careful landscape analysis for current development.
- Strategic development should consider derivatives outside the original scope, alternative synthetic routes, and new therapeutic indications.
5 FAQs
-
What is the primary application of compounds claimed in U.S. Patent 5,872,145?
The compounds are designed as kinase inhibitors for cancer treatment.
-
When did the patent expire, and how does that affect current R&D?
The patent expired in 2019, freeing the compounds' use in manufacturing and sales.
-
Are similar patents still active in this space?
Many related patents, especially those filed after 2000, may still be active, depending on jurisdictions and specific claims.
-
Can derivatives of the compounds in the patent be developed without infringement?
Possibly, if they do not fall within the scope of the patent claims, especially if they have different scaffolds or substantially different substitutions.
-
What strategic steps are advised for companies interested in pyrazole kinase inhibitors?
Conduct detailed freedom-to-operate analyses, focus on novel derivatives, explore new therapeutic indications, and consider alternative synthesis pathways.
References
[1] U.S. Patent 5,872,145. (1999). Pyrazole derivatives as kinase inhibitors. Patent Office.
More… ↓
⤷ Start Trial
|
